Hypersensitivity and streptokinase

SrS—A natural experiment is underway in the widespread treatment of patients with streptokinase (SK) to produce thrombolysis after acute myocardial infarction. The SK enzymes present in commercial products are derived from cultures of Streptococcus equisimilis (Lancefield group C), and the side-effects now being reported are relevant to research on streptococcal diseases.

Dr Callan and others (Jan 13, p 106) describe delayed hypersensitivity reactions after SK therapy. The illness in such patients features a diffuse vasculitis with rash, fever, arthralgia, proteinuria, haematuria, and sometimes impaired renal function. Immediate hypersensitivity reactions are more common than delayed reactions after SK therapy but they may be suppressed by hydrocortisone.1 In ten patients studied by Dr Argent and Dr Adams (Jan 13, p 106) symptomless proteinuria and haematuria associated with coarse granular casts in the urine occurred in all cases 4 h after SK administration, clearing by 48 h. Antibodies to SK develop in most patients treated with SK, as reported by Dr Jalihal and Mr Morris but their role in the above complications is not yet clear.

A variant SK enzyme with special affinity for the glomerular basement membrane, nephritis strain-associated protein (NSAP),2 is a strong contender as the pathogenic agent in glomerulonephritis developing after Streptococcus pyogenes infection.3 In a prospective study (ESS), another candidate,4 is thought to be an intracellular precursor of NSAP. These substances are thought to be deposited on the basement membrane with subsequent coating by antibody and complement, leading to the derangement of glomerular function; high levels of antibody to NSAP, ESS, and SK are found in patients with acute post-streptococcal nephritis.5,6 It is not known whether pre-existing antibody would protect against the development of nephritis but prospects for a vaccine have been discussed.7 Recent isolates of Lancefield group C and G streptococci from patients with nephritis have been shown to produce ESS or molecular variants of NSAP.8 In an intriguing case-report severe crescentic glomerulonephritis with cutaneous purpura developed in a patient 33 days after SK therapy for acute myocardial infarction;8 perhaps SK-induced antibody worsened the situation in this patient.

The "dose" of SK received by the patient in natural streptococcal infection is likely to be much less, and delivered more slowly, than it is in SK therapy. These factors, together with the different biological properties of SK enzymes, might lead to different patterns of injury to the vessel walls and glomerulus. The hypersensitivity effects after therapeutic injection of SK might also throw some light on the relation between streptococci and skin diseases such as acute post-streptococcal guttate polyarthritis, dermatomyositis, or urticaria; streptococcal products inducing vasculitis, such as SK, might play a part in triggering these rashes.

Department of Microbiology,
Harrogate General Hospital,
Harrogate HG2 7ND, UK

MICHAEL BARNHAM


Cyclosporin wash for oral lichen planus

SrS—Cyclosporin, when used systemically, has proved helpful in lichen planus.1,2 Unfortunately, when given by this route, cyclosporin has adverse effects that limit its use in skin diseases.3 Lichen planus affecting the oral cavity is especially difficult to treat and remissions are short-lived even when systemic corticosteroids and retinoids are used. Most topical agents are little more than palliative. We have been exploring the value of topical cyclosporin in patients with oral lichen planus.

Five women and one man aged 44–76 (mean 54) years with biopsy proven oral lichen planus were enrolled. They had had the disease for 2 years on average (range 3 months to 5 years). Topical medication was halted 2 weeks, and systemic medications 4 weeks, before the start of the study. The patients gave informed consent and the study was approved by the University of Michigan institutional review board.

In an open study patients used cyclosporin 100 mg/ml (the standard formulation for oral systemic administration). They were told to swish 5 ml (500 mg) in the oral cavity and to spit it out after 5 min. No eating or drinking was then permitted for 30 min. The treatment was repeated three times daily for 8 weeks. The same physician evaluated the patient before therapy and then in weeks 1, 2, 3, 4, 6, and 8 on a scale from 0 (no clinical disease) to 3 (severe disease). Erythema, and reticulation were assessed on this scale for vesicular erosion. A mean erosion score was calculated by summing erosion scores and dividing by the number of lesions with erosion. This was done for erythema and reticulation also. The patients graded their symptoms on a scale of 0 (no pain) to 3 (severe discomfort).

Whole blood cyclosporin levels were measured by high performance liquid chromatography (HPLC) 1 h after swishing and expectorating and routine laboratory tests were done at every visit. Representative lesions were photographed at baseline, after 4 weeks of therapy, and upon completion of the study. In four patients, 4 mm punch biopsies were done on affected buccal mucosa before and at the end of cyclosporin treatment. Immunoperoxidase staining of 5 μm cryostat sections was performed with a 'Vectastain ABC' kit (Vector Laboratories) and the following panel of monoclonal antibodies: RR 1/1 (from Dr T. Springer, Dana Farber Cancer Institute, Boston) for ICAM-1, L243 (Becton Dickinson) for HLA-DR, L610 (Becton Dickinson) for HLA-DQ and T11 (Coulter Immunology) for CD2.

All patients improved in all categories. Erythema scores fell from 2.0 (0.2) at baseline to 0.1 (0.0) after 8 weeks of topical cyclosporin (p = 0.03); erosion scores fell from 2.4 (0.5) to 0.3 (0.2) (not significant, n = 4 only); and reticulation scores decreased from 1.7 (0.2) to 0.7 (0.0) (p = 0.03). All six patients experienced significant discomfort before therapy with an average pain score of 2.2 (0.2). After treatment the pain score was only 0.1 (0.0) (p = 0.001) (complete relief noted by four patients. All six noted transient burning of the mucosal surfaces while swishing the medication. Four reported slight precipitation, resulting in waxy particles which could easily be spat out.

In four patients, cyclosporin levels in whole blood were undetectable (less than 20 ng/ml) or low (30–60 ng/ml); in the other two peaks of 176 and 184 ng/ml were recorded, but in only one of these were moderate concentrations (60–90 ng/ml) persistent. Cyclosporin levels did not correlate with clinical response. Laboratory results did not change significantly.

Before cyclosporin therapy keratinocytes of oral lichen planus expressed both ICAM-1 and HLA-DR but not HLA-DQ. In keratinocytes at the end of cyclosporin treatment ICAM-1 expression was virtually undetectable with HLA-DR expression greatly reduced. The CD2 T-lymphocyte infiltrate in the epidermis (by more than half) and in the dermis (by about one-third) was much reduced, and HLA-DR expression by T-lymphocytes in epidermis and dermis decreased in proportion. 5 months after completion of the study five patients were re-examined. No new lesions were detected and old lesions that had not completely resolved with cyclosporin remained unchanged. All six patients expressed a preference for the oral swish method over topical steroids applied previously. Spontaneous remissions in oral
ulcerative lichen planus is rare and we are confident that the clearing of active lesions in these six patients represents a response to cyclosporin.

Grattan et al treated four patients with cutaneous hypertrophic lichen planus with topical cyclosporin under occlusion and reported flattening of lesions, and in another study, four patients with oral lichen planus who applied cyclosporin to lesions with their fingers obtained partial resolution of their ulcers. However, absorption of cyclosporin through the skin is likely to be much less than absorption through oral mucosa. The mechanism of action of cyclosporin in lichen planus is unknown. However, it selectively inhibits production of interferon-γ, a lymphokine thought to be critical in the pathogenesis of lichen planus. Production of interferon-γ, a lymphokine thought to be critical in the pathogenesis of lichen planus, is known to be induced by the T lymphocytes, interferon-γ induces the expression of ICAM-1 and HLA-DR by keratinocytes. These surface molecules and their interaction with interferon-γ trigger an influx of T lymphocytes to the skin where an inflammatory reaction is established with subsequent tissue destruction.


Dermatopharmacology Unit, Department of Dermatology, and Department of Pathology, University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA

DRORE EISEN
CHARLES N. ELLIS
BRIAN J. NICKOLOFF
JOHN J. VOORHEES

Hypophosphataemic rickets and final height

Sir,—Professor Stickler and Dr Morgenstern (Oct 14, p 902) suggest that treatment of X-linked hypophosphataemic rickets with vitamin D (or one of its active derivatives) in pharmacological doses does not affect ultimate height and that clinical trials should therefore be undertaken. Our experience differs.

We had stricter diagnostic criteria than theirs (which may have included other forms of metabolic rickets) and we reported from University College Hospital the adult height of 8 patients whose vitamin D treatment was supervised by us. With Stickler and Morgenstern’s American criteria, this value was 2-10 (SD 0-69) standard deviations below the mean for healthy American males of similar age. Further 8 patients, all with positive family histories, who had been under our supervision since the age of 5 years, are now adults. Their mean height is 2-08 (0-76) SD below the American value (figure). The difference between the results of “vitamin D treatment” in the two groups can be explained either by greater severity of the disease in the USA or by differences in management and therefore of patient selection. We agree that occasionally male patients may be only mildly affected for uncertain reasons which could include variable deletions in the short arm of the X chromosome. But in most patients X-linked rickets needs careful tailoring of pharmacological vitamin D (or calcitriol or alfalcacidol) dose to individual requirements from the earliest possible age until growth ceases—on the basis of growth, radiographic appearances, serum calcium, and alkaline phosphate. Stickler and Morgenstern may have shown only that serious delay in diagnosis and/or less stringent medical management is not much better than no treatment at all. Any controlled trial of vitamin D therapy such as they seek would, at the least, pose serious ethical questions.

Metabolic Unit, Royal National Orthopaedic Hospital, Stanmore, Middlesex HA7 4LP, UK

TREVOR STAMP
A. J. GOLDSTEIN

